Research Progress on Neoadjuvant Chemotherapy and Drug Resistance for Advanced Ovarian Epithelial Carcinoma
Ovarian cancer is one of the most common malignant tumors in female reproductive system,with the third incidence rate among gynecological malignant tumors,and the first mortality rate,and epidermal ovarian cancer was the most common.According to statistics,five-year survival rate of advanced ovarian epithelial cancer was only 30%to 40%.Neoadjuvant chemotherapy refers to surgical treatment after systemic chemotherapy before surgery to shrink or disappear the tumor,which is widely used in colorectal cancer,lung cancer,breast cancer and other tumors.However,its benefits in advanced ovarian cancer are still controversial.During process of neoadjuvant chemotherapy,patients may develop drug resistance,which may cause further enlargement or spread of the lesion,and lose opportunity for surgery.Therefore,the article reviews research progress on neoadjuvant chemotherapy and drug resistance of advanced ovarian epithelial cancer.
万方数据
维普
